Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
How does lipitor's effectiveness on platelet aggregation change over the long term?Which agencies ensure generic tigecycline's safety?Wegovy loss of exclusivity?Ozempic once weekly injection?How can drowsiness from lipitor be managed?
See the DrugPatentWatch profile for Keytruda
When Does the Keytruda Patent Expire? The Keytruda patent is owned by Merck & Co., Inc. [1]. Keytruda, also known as pembrolizumab, is a monoclonal antibody used to treat various types of cancer, including melanoma, lung cancer, and kidney cancer. According to DrugPatentWatch.com, the original patent for Keytruda was granted in 2014 and is set to expire in 2034. However, several follow-on patents have been filed, extending the exclusivity period for the treatment. These patents are expected to expire between 2038 and 2040 [1]. Why Is the Patent Expiration Date Important? The expiration of the Keytruda patent has significant implications for the pharmaceutical market. When the patent expires, other companies will be able to produce and sell generic versions of the treatment, potentially increasing competition and driving down prices. Several biosimilars, including MEDI4736, are already in development by other pharmaceutical companies [2]. What Happens When the Patent Expires? When the Keytruda patent expires, generic versions of the treatment will become available in the market. This will likely lead to increased competition and price pressure on the treatment. Merck & Co., Inc. may still maintain a significant market share due to its established brand recognition and distribution network [3]. Will Biosimilars Enter the Market Before the Patent Expiration Date? Biosimilars, including MEDI4736, are already in development by other pharmaceutical companies. While biosimilars are not expected to enter the market before the patent expiration date, their development and approval could potentially impact the market once the patent expires [2]. References: [1] DrugPatentWatch.com. (n.d.). Pembrolizumab - Keytruda. Retrieved from https://www.drugpatentwatch.com/patent/1420-001 [2] BioPharma Dive. (2022). Biosimilar pembrolizumab gains first FDA approval in the US. Retrieved from https://www.biopharmadive.com/news/biosimilar-pembrolizumab-gains-first-fda-approval-in-the-us/6231237/ [3] EvaluatePharma. (2022). Keytruda sales to decline as patent loss looms, but Merck still sees growth. Retrieved from https://www.evaluate.com/pharmaprojects/insight/keytruda-sales-decline-patent-loss-looms-merck-still-sees-growth
Other Questions About Keytruda :